Fractional and Microablative CO LASER and Radiofrequency in the Treatment of Genitourinary Syndrome of Menopause: A Descriptive Study.

This study aimed to evaluate the vagina clinically, cytologically, and histologically before and after treating genitourinary syndrome of menopause (GSM) with fractional microablative carbon dioxide LASER (COL), radiofrequency (RF), and estrogen vaginal cream (CT). Women with moderate-to-severe symptoms of GSM, denoted by a GSM Visual analog scale (VAS) score of >4, were eligible for this study. The patients were randomized into treatment groups.

Women with Genitourinary Syndrome of Menopause Treated with Vaginal Estriol, Microablative Fractional CO Laser and Microablative Fractional Radiofrequency: A Randomized Pilot Study.

This pilot study intended to assess the feasibility of a large-scale randomized clinical trial designed to analyze the effectiveness of microablative fractional CO laser (COL) and microablative fractional radiofrequency (RF) compared with vaginal estriol (VE) as treatments for women with moderate-to-severe Genitourinary Syndrome of Menopause (GSM). Participants were randomized into VE, COL, or RF groups. In the VE group, women were required to use vaginal estriol cream for 14 days and then twice a week for 4 months.